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Visualization of Tumor Angiogenesis
Using MR Imaging Contrast Agent Gd-
DTPA-anti-VEGF Receptor 2 Antibody
Conjugate in a Mouse Tumor Model
Objective: To visualize tumor angiogenesis using the MRI contrast agent, Gd-
DTPA-anti-VEGF receptor 2 antibody conjugate, with a 4.7-Tesla MRI instrument
in a mouse model.
Materials and Methods: We designed a tumor angiogenesis-targeting T1 con-
trast agent that was prepared by the bioconjugation of gadolinium diethylenetri-
aminepentaacetic acid (Gd-DTPA) and an anti-vascular endothelial growth factor
receptor-2 (VEGFR2) antibody. The specific binding of the agent complex to cells
that express VEGFR2 was examined in cultured murine endothelial cells (MS-1
cells) with a 4.7-Tesla magnetic resonance imaging scanner. Angiogenesis-spe-
cific T1 enhancement was imaged with the Gd-DTPA-anti-VEGFR2 antibody
conjugate using a CT-26 adenocarcinoma tumor model in eight mice. As a con-
trol, the use of the Gd-DTPA-anti-rat immunoglobulin G (Gd-DTPA-anti-rat IgG)
was imaged with a tumor model in eight mice. Statistical significance was
assessed using the Mann-Whitney test. Tumor tissue was examined by immuno-
histochemical analysis.
Results: The Gd-DTPA-anti-VEGFR2 antibody conjugate showed predomi-
nant binding to cultured endothelial cells that expressed a high level of VEGFR2.
Signal enhancement was approximately three-fold for in vivo T1-weighted MR
imaging with the use of the Gd-DTPA-anti-VEGFR2 antibody conjugate as com-
pared with the Gd-DTPA-rat IgG in the mouse tumor model (p < 0.05). VEGFR2
expression in CT-26 tumor vessels was demonstrated using immunohistochemi-
cal staining.
Conclusion: MR imaging using the Gd-DTPA-anti-VEGFR2 antibody conju-
gate as a contrast agent is useful in visualizing noninvasively tumor angiogenesis
in a murine tumor model.
onitoring in vivo angiogenesis offers a potentially valuable surrogate
marker for the detection of tumors and the evaluation of chemotherapy
and drug efficacy. Generally, tumors cannot grow beyond 1-2 mm
3 in
diameter without the development of a vascular supply (1). Angiogenesis, the
formation of new blood vessels, is required for malignant tumor growth and metasta-
sis. Recently, several studies have shown that angiogenesis is a dynamic process by
which the blood supply of a tumor is provided by preexisting blood vessels and
endothelial precursor cells (2). Vascular endothelial growth factor (VEGF) is a
prototypical proangiogenic molecule, and VEGF has been implicated in several steps
throughout the angiogenesis process (3). Findings in other studies have shown that
VEGF is expressed at high levels for a broad spectrum of malignancies including
carcinoma of the breast (4), colon (5), ovary (6), and brain (7).
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BCA = bicinchoninic acid





Gd-DTPA-anti-rat IgG = Gd-DTPA-anti-rat
immunoglobulin G
ICAM-1 = intercellular adhesion molecule 1
ICP-MS = inductively coupled plasma
mass spectrometry
MALDI-TOF = matrix-assisted laser
desorption ionization - time of flight
MS-1 cells = murine endothelial cells 
PBS = phosphate buffered saline
SDS-PAGE = sodium dodecyl sulfate
polyacrylamide gel electrophoresis
VEGF = vascular endothelial growth
factor
VEGFR2 = vascular endothelial growth
factor receptor-2
MMRI is a highly useful noninvasive imaging method with
sub-millimeter resolution and high tissue contrast.
Furthermore, MRI enhanced with contrast agent can be
used to characterize microvessels of tumors quantitatively
and can thereby be used to assess angiogenesis (8). For
instance, Gd-based contrast agent can be used to detect
early tumor with the use of MRI instrument (9). The use of
Gd-based contrast agents provides strong positive T1
relaxation contrast. In addition, Gd-based contrast agents
have traditionally been used for non-specific contrast-
enhanced clinical MRI. Recently, this approach has been
successfully used to image the neovasculature in
angiogenic tumors with MRI (10-12).
The use of Gd-based contrast agents; however, cannot
provide molecular-specific information. For visualization
of molecular information for cell surface antigens and/or
receptors in vivo, the use of molecular targeted agents can
be used. This method relies on the specific labeling of
extracellular cell surface receptors or antigens with an MRI
targeted contrast agent. MRI contrast agent can be specifi-
cally targeted with a monoclonal antibody (mAb) that
binds with high affinity to a specific receptor or antigen.
Imaging of tumors that express VEGFR2 has been
attempted using a compound synthesized by the conjuga-
tion of avidin-Gd and biotinylated anti-VEGFR2 antibody
for the visualization of tumor angiogenesis (13). However,
avidin and biotin are expected to cause potentially
unfavorable effects such as difficulties in humanization and
tissue clearance of the avidin from the patient’s body. As a
result, we used a direct conjugation method for Gd-DTPA
and anti-VEGFR2 antibody, as previously described by our
laboratory (14).
Based on the above considerations, we hypothesized
that the Gd-DTPA targeted for tumor vasculature via the
conjugation with an anti-VEGF R2 antibody that binds to
tumor cells would result in increased contrast enhance-
ment during the MR imaging of solid tumors using a
murine model. The purpose of this study was to evaluate
the use of a novel contrast agent, the Gd-DTPA-anti-
VEGFR2 antibody conjugate, to visualize tumor angiogen-
esis with 4.7-Tesla (T) animal MR imaging using a mouse
model.
MATERIALS AND METHODS
Preparation of the Gd-DTPA-anti VEGFR2 Antibody
Conjugate
The preparation of the contrast agent, Gd-DTPA-anti-
VEGFR2 antibody conjugate (Fig. 1), was based on a
similar method previously described by our laboratory (14)
for the preparation of the contrast agent Gd-DTPA-anti-
intercellular adhesion molecule 1 (ICAM-1). The VEGFR2
antibody was purified from the culture supernatant of rat
hybridoma using protein A/G-coupled affinity chromatog-
raphy. Purified antibodies were identified by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), Western blot analysis, and bicinchoninic acid
(BCA) assay. Diethylenetriaminepentaacetic acid bisanhy-
dride (DTPABA) was dissolved in dimethylformamide and
then added to the antibody solution. The anti-VEGFR2
antibody was conjugated to DTPABA in phosphate-
buffered saline (PBS) (pH 8.5) for one hour at room
temperature. The reaction solution was purified using a
PD-10 column (Sephadex G-25M, Amersham Biosciences,
Amersham, UK). The concentration of the antibody was
measured using the BCA assay. Gd chloride was dissolved
in deionized water and then added to the DTPA-antibody
conjugate solution. One part of the DTPA-antibody
complex was then reacted with 40 parts of Gd chloride in
0.5 M sodium acetate (pH 5.5). The solution was loaded
onto a PD-10 column and was eluted from the column
with 0.15 M NaCl (pH 5.5). Gd-DTPA antibody conjugates
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taacetic acid bisanhydride, mAb =
monoclonal antibody (anti-VEGFR 2
antibody), PBS = phosphate-buffered
saline, Gd = gadoliniumwere analyzed using matrix-assisted laser desorption
ionization - time of flight (MALDI-TOF) (Voyager-DE STR
4349) spectrometry. The Gd content was determined with
the aid of inductively coupled plasma mass spectrometry
(ICP-MS) (Agilent 7500A, Agilent Technologies, Palo
Alto, CA), and the final concentration of the conjugated
antibody was measured using BCA analysis. The molar
ratio of gadolinium and antibody was then calculated. The
control antibody conjugate, Gd-DTPA-anti-rat-IgG, was
prepared using a similar method.
Cell Culture
A rat hybridoma used for the isolation of anti-VEGFR2
antibody was purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and was cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 mM
L-glutamine, which was adjusted to contain 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, and 10% fetal bovine serum.
The murine endothelial cell line (MS-1) and murine colon
adenocarcinoma cell line (CT-26) were also obtained from
ATCC and the cells were cultured according to the
supplier’s instructions. Cells were grown as monolayer
cultures in DMEM with 10% fetal bovine serum
(Invitrogen, Grand Island, NY) supplemented with 1%
glutamine and 1% antibiotics. Cells were maintained in a
37 ℃ incubator in 5% CO2 humidified air.
For the preparation of the endothelial cell-specific
contrast effect, MS-1 cells (5 × 10
6) were cultured and
were incubated with the Gd-DTPA-VEGFR2 antibody
complexes (300 nmol Gd) in the presence or absence of
anti-VEGFR2 antibody (600 nmol) at 4 ℃ for four hours.
The cells were then washed three times with PBS,
harvested by scraping, and pelleted by centrifugation.
In Vitro MR Imaging
In vitro MRI was performed on a 4.7-T animal MRI
instrument (Bruker, Ettlingen, Germany). The endothelial
cell-specific contrast effect was assessed by determining
MRI contrast effects with the endothelial MS-1 cells. An
MR image of the cells in the tubes placed in a water-filled
chamber was obtained with a spin echo sequence using the
following imaging parameters: TR = 300 milliseconds, TE =
10 milliseconds, field of view (FOV) = 25.6 mm × 25.6
mm, slice thickness = 1 mm, pixel resolution = 100 × 100
μ m, in the 4.7-T instrument. The signal intensity of T1-
weighted imaging (WI) of the cell pellets was normalized
against that of the surrounding water. Each experiment
was performed in triplicate and the signal intensity was
shown as the mean ± standard deviation.
A region of interest (ROI = 0.02 cm
2) for cell and water
was calculated. The average of the ROIs included areas of
maximal and minimal enhancement in each slice. For the in
vitro MRI study, we defined the relative signal intensity
(SI) as: ([mean of ROI] cell) / ([mean of ROI] water).
Mouse Tumor Model
Male Balb/c nude mice (n = 16, aged 6 weeks and each
weighing 20-25 g) were purchased from the Central
Animal Laboratory (Seoul, South Korea) and used for this
study. The Balb/c nude mice were injected subcutaneously
in their back with CT-26 cells (1 × 10
6 cells) suspended in
0.1 mL phosphate-buffered saline. The injected cells were
allowed to expand for 10 days until the tumors grew to a
size approximately 0.5 cm
3.
In Vivo MR Imaging
In vivo MRI was performed on a 4.7-T animal MRI
instrument. T1WI was obtained at 10 minutes and at 12,
24, and 48 hours after the injection of the Gd-DTPA-anti-
VEGFR2 antibody conjugate (12 μ mol of Gd/kg of body
weight) in eight mice, followed by the injection of the Gd-
DTPA-anti-rat IgG conjugate (12 μ mol of Gd/kg of body
weight) in another eight mice. All the animals were
examined by contrast-enhanced T1-weighted MRI using
the following imaging parameters: TR = 300 milliseconds,
TE = 10 milliseconds, FOV = 25.6 mm × 25.6 mm, slice
thickness =1 mm, pixel resolution = 100 ×100 μ m, in the
4.7-T instrument. All of the animal studies were carried
out in accordance with the regulations set by the
Institutional Review Board of our university.
An ROI (= 0.02 cm
2) for the tumor center and muscle
was calculated for the mean value. The average of the
ROIs included areas of maximal and minimal enhancement
in each slice. The SI was calculated using the following
equations: SI = ([mean of ROI] tumor) / ([mean of ROI]
muscle). For the in vivo MRI study, we defined the contrast
enhancement ratio (CER) as ([SIpost - SIpre] / SIpre) ×
100%, where SIpre = signal intensity before administration
of contrast medium and SIpost = signal intensity after
contrast medium administration.
Immunohistochemical Analysis
After analyzing the mice by MRI, tumor tissue was
collected and the expression of VEGFR2 was then examined
by way of an immunohistochemical analysis. Tissue sections
were fixed with 4% paraformaldehyde and sections were
reacted with rabbit anti-mouse VEGFR2 antibody for two
hours at 37 ℃. The primary antibody that bound to
VEGFR2 and expressed in cells was then visualized with a
secondary peroxidase-conjugated antibody and substrate
dye. To detect the injected Gd-DTPA-anti-VEGFR2
antibody, an adjacent section was incubated with only the
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conjugated antibody (rabbit anti-mouse VEGFR2 antibody)
and was detected with the substrate dye.
Statistical Analysis
The data were presented as the mean ± standard
deviation, and the significance of the data was assessed
using the Mann-Whitney test. The statistical analyses were
performed using commercial software (SPSS, Chicago, IL).
RESULTS
Preparation of the Gd-DTPA-Anti-VEGFR2 Antibody
Conjugate
The purified antibody fraction was identified by SDS-
PAGE (separating the 50 kDa and 25 kDa) of the IgG.
These antibody fragments were also identified using
Western blot analysis, which also detected the 50 kDa and
25 kDa. The intermediate product, DTPA antibody, and
the final product, Gd-DTPA antibody, were quantified by
BCA assay for their antibody content and were character-
ized using MALDI-TOF spectrometry analysis for the
conjugated product. The molecular weight shift from anti-
VEGFR2 to Gd-DTPA-anti-VEGFR2 antibody in MALDI-
TOF spectrometry analysis represents the conjugation of
the antibody with Gd-DTPA. A quantitative analysis of the
Gd content in the Gd-DTPA-antibody was performed
using ICP-MS. The molar ratio of Gd to antibody was
about 1:20.
VEGFR2-Specific MRI with the Gd-DTPA-Anti-VEGFR2
Antibody Conjugate in Cultured Endothelial Cells
To examine whether the Gd-DTPA-anti-VEGFR2
antibody conjugate can bind to cells in a VEGFR2-specific
manner, the contrast agent was incubated with MS-1 cells
in the presence or absence of a competitive binding
inhibitor, the anti-VEGFR2 antibody (Fig. 2). The competi-
tive antibody was added at a three-fold higher concentra-
tion than the anti-VEGFR2 antibody content of the Gd-
DTPA-anti-VEGFR2 antibody complex. The value of
signal intensity showed that binding of the Gd-DTPA-anti-
VEGFR2 antibody complex to the VEGFR2-expressing
cells was significantly inhibited by competition with the
anti-VEGFR2 antibody (Table 1). 
Angiogenesis-Specific MRI with the Gd-DTPA-Anti-
VEGFR2 Antibody Conjugate in a Mouse Tumor
Model
Angiogenesis-targeted MRI using the Gd-DTPA-anti-
VEGFR2 antibody conjugate was examined in a mouse
tumor model. The Gd-DTPA-anti-VEGFR2 antibody
conjugate displayed significant signal enhancement and
accumulation of tumor tissues until 48 hours after contrast
agent injection (Fig. 3A-E). The Gd-DTPA-anti-rat IgG and
the Gd-conjugated control antibody containing the same
amount of Gd as the Gd-DTPA-anti-VEGFR2 antibody
conjugate, showed no significant enhancement in T1 until
48 hours after injection (Fig. 3F-J). The CER in the mouse
tumors that received Gd-DTPA-anti-VEGFR2 antibody
conjugate increased at 24 hours (29%) and at 48 hours
(9%) after injection. Conversely, the CER in the mouse
tumors that received Gd-DTPA-anti-rat IgG was increased
at 24 hours (11%) and at 48 hours (11%) after injection.
The CER value was significantly different for mouse
tumors that were  administered Gd-DTPA-anti-VEGFR2
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Fig. 2. T1-weighted MR images using Gd-DTPA-anti-VEGFR2
antibody in cultured endothelial cells are shown. 
A. MS-1 cells were not treated with either contrast or control
agent. 
B. VEGFR2 expressing MS-1 cells treated with Gd-DTPA-anti-
VEGFR2 antibody shows significant increase in high signal
intensity. 
C. MS-1 cells show no high signal on T1-weighted imaging with
Gd-DTPA-anti-VEGFR2 antibody in presence of competitive
binding inhibitor, anti-VEGFR2 antibody.
Table 1. Signal Intensity for Murine Endothelial Cells as




Gd-DTPA-anti-VEGFR2 antibody + anti- 1.1051
VEGFR2 antibody
Note.─ *SI = relative signal intensityantibody conjugate and Gd-DTPA-anti-rat IgG (p < 0.05).
The Gd-DTPA-anti-VEGFR2 antibody conjugate injected
into tumors showed a peak time at 24 hours. Conversely,
Gd-DTPA-anti-rat IgG injected into tumors showed a peak
time at 24 hours with a low level of enhancement (Fig. 3).
Immunohistochemical Analysis
CT-26 tumor tissue was examined using immunohisto-
chemical staining for VEGFR2 expression to assess
whether the angiogenesis-specific imaging, using the Gd-
DTPA-anti-VEGFR2 antibody, corresponded to VEGFR2
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Fig. 3. In vivo dynamic MR imaging of
tumors is shown at 10 minutes and at
12, 24 and 48 hours following injection
of Gd-DTPA-anti-VEGFR2 antibody
conjugate (A-E) as well as injection of
Gd-DTPA-anti-rat IgG (F-J). Both
contrast agents were injected at same
dose. Gd-DTPA-anti-VEGFR2 antibody
conjugate shows significant signal
enhancement and accumulation in
tumor tissues until 48 hours after
contrast agent injection. Comparatively,
Gd-DTPA-anti-rat IgG shows no signifi-



















Fexpression in tumors. The expression of VEGFR2 showed
an extremely high level in vessels of CT-26 tumor tissue
(Fig. 4).
DISCUSSION
The ability of tumors to induce new blood-vessel
formation has been a major focus of cancer research over
the past few decades, and VEGF is now known to have a
central role in this process (15). Vascular endothelial
growth factor-A (VEGF-A) is one of the factors responsible
for new blood-vessel formation in the VEGF family (16-
20). VEGF-A, a major regulator of angiogenesis, binds and
activates two tyrosine kinase receptors, VEGFR1 (Flt-1)
and VEGFR2 (KDR/Flk-1). These receptors regulate
physiological as well as pathological angiogenesis. VEGFR2
has a strong tyrosine kinase activity, and the protein
transduces the major signals for angiogenesis. VEGFR2
expression is 3-5-fold higher in tumor vasculature as
compared to normal vasculature (21). The specificity of
VEGFR2 expression, the location of VEGFR2 on the
surface of the tumor vessels, and the predominant role of
the receptor in tumor angiogenesis, makes the receptor a
highly desirable target for the development of both anti-
angiogenic and vascular-targeting agents.
The targeting of contrast agents for specific tissue
markers has been suggested to be useful in selecting
imaging agents for the detection and evaluation of vascular
pathology, including thrombosis, inflammation, tumor
angiogenesis, or therapeutic angiogenesis (22, 23). For
instance, P-selectin (24) and ICAM-1 (25) are known to be
up-regulated on the surface of activated endothelium in
tissue involved in inflammatory processes. A number of
endothelial markers such as α vβ 3 (26) and the VEGF
receptors (15-20, 27) are up-regulated on the endothelium
surface during angiogenesis.
The monitoring of tumor angiogenesis can involve
several types of imaging equipment. Studies have been
conducted with MRI, positron emission tomography (PET),
bioluminescence imaging, and fluorescence optical
imaging. Of these modalities, MRI is capable of providing
both high-resolution anatomical information and functional
measurements of tumor physiology (28-30).
In this study, we anticipated that we would be able to
visualize tumor angiogenesis with the use of a novel
contrast agent, Gd-DTPA anti-VEGF receptor 2 antibody
conjugate, in a mouse model. For the in vitro study, we
first showed that binding of the contrast agent, Gd-DTPA
anti-VEGFR2 antibody conjugate, to MS-1 cells resulted in
a higher signal intensity compared to non-treated MS-1
cells. Moreover, pre-incubation with anti-VEGFR2
antibody inhibited the signal intensity seen for the MS-1
cells. These findings indicate that Gd-DTPA anti-VEGFR2
antibody conjugate binds to the VEGFR2-expressing MS-1
cells, thereby suggesting that the Gd-DTPA-anti-VEGFR2
antibody conjugate is a useful MRI contrast agent for the
visualization of tumor angiogenesis. Subsequently, we
assessed tumor angiogenesis in vivo. We used two agents
for contrast signal enhancement of the Gd-DTPA-anti-
VEGFR2 antibody conjugate and, as a control, the Gd-
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Fig. 4. Histopathological examination results.
A. Hematoxylin and eosin staining shows tumor tissue. 
B. Tissue was stained with rabbit anti-mouse VEGFR2 (Flk-1) antibody for immunohistochemical analysis, indicating expression of
VEGFR2 in vessels (arrows) of CT-26 tumor tissue (× 400 magnification).
ABDTPA-anti-rat IgG. A long period of enhancement was
observed when using the Gd-DTPA-anti-VEGFR2
antibody conjugate, with an approximately three-fold
enhancement ratio compared to when the Gd-DTPA-anti-
rat IgG was used. The peak enhancement time when using
Gd-DTPA-anti-VEGFR2 antibody conjugate was delayed
compared to the peak enhancement time when using the
Gd-DTPA-anti-rat IgG. These findings indicate that the
Gd-DTPA-anti-VEGFR2 antibody conjugate binds to the
tumor vessel endothelial cell. The elevated expression of
VEGFR2 in tumor vessels was confirmed with immunohis-
tochemical staining.
In conclusion, the results of this study suggest that the
use of the MRI contrast agent, Gd-DTPA-anti-VEGFR2
antibody conjugate allows for the noninvasive visualiza-
tion of tumor angiogenesis in a mouse model. These
findings should have direct implications for future monitor-
ing of anti-tumor and anti-angiogenic therapies.
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